Drug intelligence / Profile preview

triamcinolone acetonide + neomycin sulfate + gramicidin

Development stage
Unknown
Lead developer
Bristol Myers Squibb
Modality
Peptides, Small Molecules
Administration
Topical, Otic
01

Overview

This is a **combination topical drug** comprised of three active ingredients: - **Triamcinolone acetonide**: a synthetic corticosteroid that reduces inflammation, itching, and swelling by inhibiting the production of inflammatory mediators.(*Mechanism*: binds to glucocorticoid receptor, modulating transcription and suppressing pro-inflammatory genes) - **Neomycin sulfate**: an aminoglycoside antibiotic that binds to the 30S ribosomal subunit of bacteria, inhibiting protein synthesis and leading to bacterial cell death. - **Gramicidin**: a peptide antibiotic that increases bacterial cell membrane permeability, leading to cell death. This drug is used primarily for **topical treatment of skin or ear infections** that involve or may involve inflammation and bacterial infection. It may be used in corticosteroid-responsive dermatoses, otitis externa, or external ear infections. It is NOT for systemic use(*inhalation or ingestion*), and should not be used if there is a perforated eardrum or certain viral/fungal infections. Extended use can cause sensitization or toxicity (e.g., ototoxicity with neomycin)[1][4][6][8].

Brand names
Kenacomb OticOtocomb OticTri-Adcortyl
Other names
triamcinolone acetonide/neomycin sulfate/gramicidintriamcinoloneneomycingramicidin
02

Targets

Bacterial RibosomeGR (Glucocorticoid receptor)

Beyond the preview

Go deeper on triamcinolone acetonide + neomycin sulfate + gramicidin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on triamcinolone acetonide + neomycin sulfate + gramicidin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call